Economic analysis of erythropoietin use in orthopaedic surgery

Transfusion Medicine

Volumn 9, Issue 1, 1999, Pages 21-30

  Coyle, D ^a,b   Lee, K M ^a   Fergusson, D A ^a   Laupacis, A ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Blood transfusion; Cost effectiveness; Erythropoietin

Indexed keywords

ERYTHROPOIETIN;

ALLOTRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; META ANALYSIS; METHODOLOGY; ORTHOPEDICS; PEROPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

BLOOD TRANSFUSION; CANADA; COST-BENEFIT ANALYSIS; ERYTHROPOIETIN; HUMANS; INTRAOPERATIVE CARE; META-ANALYSIS; ORTHOPEDICS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033104249     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3148.1999.009001021.x     Document Type: Article

References (56)

1. Andrews, R.M., Keyes, M.A., Fanning, T.R. & Kizer, K.W. (1991) Lifetime medicaid service utilization and expenditures for AIDS in New York and California. Journal of Acquired Immune Deficiency Syndromes, 4, 1046-1058.
2. Andrulis, D.P., Weslowski, V.B., Hintz, E. & Spolarich, A.W. (1992) Comparisons of hospital care for patients with AIDS and other HIV-related conditions. Journal of American Medical Association, 267, 2482-2486.
3. Anon. (1991) Public service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Morbidity Mortality Weekly Report, 40, 1-17.
4. Anon. (1997) Blood supply: Transfusion-associated risks. General Accounting Office, Washington, DC.
5. Beris, P., Mermillod, B., Levy, G., et al. (1993) Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sanguinis, 65, 212-218.
6. Biesma, D.H., Kraaijenhagen, R.J., Marx, J.J. & van de Wiel, A. (1993) The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomyinduced anemia in autologous blood donors. Transfusion, 33, 825-829.
7. Biesma, D.H., Marx, J.J.M., Kraaijenhagen, R.J., Franle, W., Messinger, D. & van de Wiel, A. (1994) Lower homologous blood requirement in autologous blood donors after treatment with recombinant erythropoietin, Lancet, 344, 367-370.
8. Birkmeyer, J.D., Goodnough, L.T., AuBuchon, J.P., Noordsij, P.G. & Littenberg, B. (1993) The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 33, 544-551.
9. Birkmeyer, J.D., AuBachon, J.P., Littenberg, B., O'Connor, G.T., Nease, R.F., Jr, Nugent, W.C. & Goodnough, L.T. (1994) Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Annals of Thoracic Surgery, 57, 161-168.
10. Brettle, R.P., Willock, I., Cowan, R.M. & Richardson, A.M. (1994) Inpatient health care utilization for patients with HIV and AIDS in Edinburgh city hospital. Internal Journal of STD and AIDS, 5, 194-201.
11. Brettle, R.P., Atkinson, F.I., Wilcock, J., et al. (1997) The cost of health care for HIV-positive patients. International Journal of STD and AIDS, 8, 50-53.
12. CCOHTA (1994) Guidelines for the economic evaluation of pharmaceuticals. CCOHTA, Ottawa, Canada.
13. COPESG (Canadian Orthopedic Perioperative Erythropoietin Study Group). (1993) Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet, 341, 1227-1232.
14. de Andrade, J.R., Jove, M., Landon, G., Frei, D., Guilfoyle, M. & Young, D.C. (1998) Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. American Journal of Orthopedics, 25, 533-542.
15. Donahue, J.D., Munoz, A., Ness, P.M., Brown, D.E., Yawn, D.H., McAllister, H.A., Reitz, B.A. & Nelson, K.E. (1992) The declining risk of post-transfusion hepatitis C virus infection. New England Journal of Medicine, 327, 369-373.
16. Elawad, A., Benoni, G., Montgomery, F., Hyddmark, U., Persson, U. & Fredin, H. (1991) Cost effectiveness of blood substitution in elective orthopedic operations. Acta Orthopaedica Scandinavica, 62, 435-439.
17. Etchason, J., Petz, L., Keeler, E., et al. (1995) The cost effectiveness of preoperative autologous blood donations. New England Journal of Medicine, 332, 719-24.
18. Faris, P.M., Ritter, M.A., Abels, R.I., American Erythropoietin Study Group. (1996) The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. Journal of Bone and Joint Surgery American Volume, 78-A, 62-72.
19. Fortgang, I.S. & Moore, R.D. (1995) Hospital admission of HIV-infected patients from 1988 to 1992 in Maryland. Journal of Acquired Immune Deficiency Syndrome Human Retrovirology, 8, 365-372.
20. Gable, C.B., Tierce, J.C., Simison, D., Ward, D. & Motte, K. (1996) Cost of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. Journal of Acquired Immune Deficiency Human Retrovirology, 12, 413-420.
21. Gibis, B. (1997) Leukodepletion - an investigation into the techniques used, their effectiveness and costs. CCOHTA, Ottawa, Canada.
22. Goel, V., Deber, R. & Detsky, A.S. (1989) Nonionic contrast media: economic analysis and health policy development. Canadian Medical Association Journal, 140, 389-395.
23. Gold, M., Gafni, A., Nelligan, P. & Millson, P. (1997) Needle exchange programs: an economic evaluation of a local experience. Canadian Medical Association Journal 157, 255-262.
24. Goodnough, L.T., Rudnick, S., Price, T.H., et al. (1989) Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. New England Journal of Medicine, 321, 1163-1168.
25. Goodnough, L.T., Price, T.H., Friedman, K.D., et al. (1994) A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion, 34, 66-71.
26. Healy, J.C., Frankforter, S.A., Graves, B.K. & Reddy, R.L. (1994) Preoperative autologous blood donation in total-hip arthroplasty. Archives of Pathology Laboratory Medicine, 118, 465-470.
27. Hellinger, F.J. (1993) The lifetime cost of treating a person with HIV. Journal of the American Medical Association, 270, 474-478.
28. Hillner, B.E., Smith, T.J. & Desch, C.E. (1992) Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analyses while awaiting clinical trial results. Journal of the American Medical Association, 267, 2055-2061.
29. Huber, T.S., McGorray, S.P., Carlton, L.C., Irwin, P.B., Flug, R.R., Flynn, T.C. & Seeger, J.M. (1997) Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. Journal of Vascular Surgery 25, 984-994.
30. Krever, H. (1995) Interim report of the Commission of Inquiry on the Blood System in Canada. Ministry of Supply and Services Canada, Ottawa, Canada.
31. Lackritz, E.M., Satten, G.A., Aberle-Grasse, J., Dodd, R.Y., Raimondi, V.P., Janssen, R.S. et al. (1995) Estimated risk of transfusion of the human immunodeficiency virus by screened blood in the United States. New England Journal of Medicine 333, 1721-1725.
32. Laupacis, A., Feeny, D., Detsky, A.S., Tugwell, P.X. (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal 146, 473-481.
33. Laupacis, A. & Fergusson, D. (1998) Erythropoietin to minimize perioperative blood transfusion: four meta-analyses. Transfusion Medicine.
34. Linden, J.V. & Kaplan, H.S. (1994) Transfusion errors: causes and effects. Transfusion Medicine Reviews, 9, 169-183.
35. McAlister, F.A., Clark, H.D., Wells, P.S. & Laupacis, A. (1998) Perioperative allogeneic blood transfusions do not cause adverse sequelae in cancer patients: a meta-analysis of unconfounded studies. British Journal of Surgery 85, 171-8.
36. Mah, E.T., Davis, R., Seshadri, P., Nyman, T.M.L. & Seshadri, N.R. (1995) The role of autologous blood transfusion in joint replacement surgery. Anaesthesia and Intensive Care, 23, 472-477.
37. Mercuriali, F., Zanella, A., Barosi, G.H., et al. (1993) Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion, 33, 55-60.
38. Mesmer, K. (1996) Consensus statement: using epoetin alfa to decrease the risk of allogeneic blood transfusion in the surgical setting. Seminars in Haematology, 33, 78-80.
39. Monk, T.G., Goodnough, L.T., Birkmeyer, J.D., Brecher, M.E., Catalona, W.J. (1995) Acute normovolemic haemodilution us a cost-effective alternative to preoperative autologous blood domain by patients undergoing radical retropubic prostatectomy. Transfusion, 35, 559-565.
40. Murphy, P.J., Connery, C., Hicks, G.L. & Blumberg, N. (1992) Homologous blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. Journal of Thoracic and Cardiovascular Surgery, 104, 1092-1099.
41. Nelson, K.E., Donahue, J.G., Munoz, A., et al. (1992) Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. Annuals of Internal Medicine, 117, 554-559.
42. Petrou, S., Dooley, M., Whitaker, L., et al. (1996) The economic costs of caring for people with HIV infection and AIDS in England and Wales. Pharmaco Economics, 9, 332-340.
43. Price, T.H., Goodnough, L.T., Vogler, W.R., et al. (1996) The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits - a multicenter, randomized, double-blind, controlled trial. Transfusion, 36, 29-36.
44. Roberts, W.A., Kirkley, S.A. & Newby, M. (1996) A cost comparison of allogeneic and preoperatively or intraoperatively donated autologous blood. Anesthesia and Analgesia, 83, 129-133.
45. Schlaeppi, B., Gunter, P. & Nydegger, U.E. (1994) Enhancing the efficacy of preoperative autologous blood donation by erythropoietin. Transfusion Science, 15, 171-177.
46. Schreiber, G.B., Busch, M.P., Kleinman, S.H., Korelitz, J.J. for the Retrovirus Epidemiology Donor Study. (1996) The risk of transfusion-transmitted viral infections. New England Journal of Medicine, 334, 1685-1690.
47. Scott, W.J., Rode, R., Castlemain, B., Kessler, R., Follis, F., Pett, S.B. & Wernly, J.A. (1992) Efficacy, complications, and cost of comprehensive blood conservation program for cardiac operations. Journal of Thoracic and Cardiovascular Surgery, 103, 1001-1007.
48. Solomon, M.D., Rutledge, M.L., Kane, L.E. & Yawn, D.H. (1988) Cost comparison of intraoperative autologous versus homologous transfusion. Transfusion, 28, 379-382.
49. Statistics Canada. (1990-92) Life Tables, Canada and Provinces 1990-1992. (Catalogue 84-537 Occasional) Statistics Canada, Ottawa, Ontario.
50. Tretiak, R., Laupacis, A., Riviere, M., McKerracher, K., Souetre, E., Benefit Research Group. (1996) Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group. Canadian Medical Association Journal, 154, 1501-8.
51. Tryba, M., Kindler, D. & Schulte-Tamburen, A. (1995) Preoperative use of low dose human erythropoietin in combination with parenteral iron substitution for the stimulation of autologous blood donation in patients before elective orthopaedic surgical interventions. The role of epoetin alpha in surgery. In: Forging the Link in Blood Conservation, 6-7. Adelphi Communications.
52. von Bormann, B., Weidler, B., Friedrich, M. & von AndrianWerburg, H. (1991) Recombinant erythropoietin in autologous blood donation. Anaesthesist, 40, 386-390.
53. Walker, R.H. (1987) Special report: transfusion risks. American Journal of Clinical Pathology, 88, 374-378.
54. Weinstein, M.C. & Stason, W.B. (1985) Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annual Review of Public Health, 6, 41-63.
55. Yuen, K. & Matthews, J.P. (1995) Recombinant human erythropoietin (R-HuEPO) and autologous donation. Janssen Cilag Limited.
56. Zowall, H., Coupal, L., Fraser, R.D., Gilmore, N., Deutsch, A. & Grover, S.A. (1992) Economic impact of HIV infection and coronary heart disease in immigrants to Canada. Canadian Medical Association Journal, 147, 1163-1172.